Covis Pharma Canada announced that it has signed a 7-year promotion and distribution agreement with Novartis Pharmaceuticals Canada for exclusive rights to Seebri Breezhaler glycopyrronium DPI and Ultibro Breezhaler indacaterol / glycopyrronium for the treatment of COPD in Canada.
In November 2021, Covis announced that it had acquired global rights to market AstraZeneca’s Eklira (Turdorza, Bretaris) aclidinium bromide and Duaklir (Brimica) aclidinium bromide/formoterol DPIs. The company acquired global rights to Alvesco MDI and Omnaris and Zetonna nasal sprays from AstraZeneca in 2018.
Covis Senior VP and General Manager for Canada James Hall said, “This agreement for the Canadian market, following closely on the recent global acquisition of COPD medications Tudorza and Duaklir from AstraZeneca, allows us to provide a range of therapeutic options for Canadians with COPD. Alongside Alvesco (ciclesonide) for the treatment of asthma, and Omnaris for the treatment of allergic rhinitis, these medicines for COPD reinforce our commitment to patients with respiratory conditions and their healthcare providers.”
Novartis Pharmaceuticals Canada Head Andrea Marazzi commented, “This agreement with Covis is aligned with our goal of providing innovative medicines to improve and transform patients’ lives. The addition of Seebri Breezhaler and Ultibro Breezhaler to Covis’ portfolio of COPD medications means that more Canadians will benefit.”
Read the Covis Pharma press release.
